ASCLERA
LOE Approachingpolidocanol
NDAINTRAVENOUSSOLUTION
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
Sclerosing Activity
Pharmacologic Class:
Sclerosing Agent
Clinical Trials (1)
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
Started Jun 2003